Ser67
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.7
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser67  -  PPP1R1A (human)

Site Information
LKSTLAMsPRQRKKM   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447758

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 ) , mutation of modification site ( 8 ) , phospho-antibody ( 9 , 10 ) , western blotting ( 8 , 9 , 10 )
Disease tissue studied:
breast cancer ( 2 ) , breast ductal carcinoma ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 2 ) , lung cancer ( 5 ) , non-small cell lung cancer ( 5 ) , pancreatic ductal adenocarcinoma ( 4 )
Relevant cell line - cell type - tissue:
'muscle, skeletal' ( 6 , 7 ) , 'pancreatic, ductal'-pancreas ( 4 ) , breast ( 1 , 2 ) , heart ( 10 ) , liver ( 3 ) , myocyte-heart ( 8 , 9 ) , NCI-H1395 (pulmonary) ( 5 ) , NCI-H2030 (pulmonary) ( 5 )

Upstream Regulation
Kinases, in vitro:
CDK5 (cow) ( 11 ) , PKACA (human) ( 8 ) , PKCA (human) ( 9 )
Phosphatases, in vitro:
PPP1CA (human) ( 11 )
Treatments:
heart failure ( 10 )

Downstream Regulation
Effects of modification on PPP1R1A:
enzymatic activity, induced ( 11 ) , phosphorylation ( 8 )
Effects of modification on biological processes:
cytoskeletal reorganization ( 8 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

3

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

4

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

5

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

6

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

7

Højlund K, et al. (2009) In vivo phosphoproteome of human skeletal muscle revealed by phosphopeptide enrichment and HPLC-ESI-MS/MS. J Proteome Res 8, 4954-65
19764811   Curated Info

8

Rodriguez P, et al. (2007) Phosphorylation of human inhibitor-1 at Ser67 and/or Thr75 attenuates stimulatory effects of protein kinase A signaling in cardiac myocytes. Am J Physiol Heart Circ Physiol 293, H762-9
17416610   Curated Info

9

Rodriguez P, Mitton B, Waggoner JR, Kranias EG (2006) Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function. J Biol Chem 281, 38599-608
17046826   Curated Info

10

Braz JC, et al. (2004) PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 10, 248-54
14966518   Curated Info

11

Huang KX, Paudel HK (2000) Ser67-phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor. Proc Natl Acad Sci U S A 97, 5824-9
10811908   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.